Traders should monitor the sBLA submission for Ziihera in first-line GEA in 1Q 2026 and potential NCCN guideline inclusion as near-term catalysts. The Royalty Pharma financing de-risks the balance sheet and extends cash runway beyond 2028, supporting continued buybacks or strategic acquisitions. Upcoming data presentations at AACR in April 2026 could provide additional R&D momentum.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $23.31entry
- T+1 · 9mo ago +4.89%α +5.81% · $24.45
- T+5 · 8mo ago +4.03%α +5.24% · $24.25
- T+20 · 8mo ago +3.86%α +11.80% · $24.21
- T+60 · 6mo ago +8.97%α −0.36% · $25.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34% reduction in net loss to $81.1 million. The company secured $250.0 million in non-dilutive financing from Royalty Pharma and is executing a $125.0 million share repurchase program, having already used $62.5 million. Key catalysts include the potential U.S. approval and 2026 launch of Ziihera in first-line HER2+ gastroesophageal cancer, which could trigger up to $440.0 million in milestone payments.
Key Financial Metrics
Key Facts
- Total revenue for 2025 was $106.0 million, up 39% from $76.3 million in 2024
- Net loss for 2025 was $81.1 million, a 34% improvement from $122.7 million in 2024
- Entered into $250.0 million non-recourse royalty-backed note financing with Royalty Pharma
- Utilized $62.5 million of a $125.0 million share repurchase program as of March 2, 2026
- Partner Jazz expects to submit sBLA for Ziihera in first-line HER2+ GEA in 1Q 2026 with potential U.S. launch in 2H 2026
- Eligible for up to $440.0 million in milestone payments from Jazz and BeOne for Ziihera approvals in GEA across U.S., Europe, Japan, and China
- Cash, cash equivalents, and marketable securities totaled $270.6 million as of December 31, 2025
- Guided for approximately $300.0 million in adjusted gross operating expenses (non-GAAP) over 2026–2028, with 2026 expenses ~20% lower than 2025
Financial Impact
Revenue increased by $29.7 million YoY; net loss reduced by $41.6 million; $250.0 million non-dilutive financing secured; $62.5 million returned to shareholders via buybacks
Risk Factors
- Regulatory delay or rejection of Ziihera sBLA in first-line GEA
- Failure to realize anticipated milestone payments from partners
- Clinical setbacks in wholly-owned pipeline programs (ZW191, ZW251, ZW209, ZW1528)
- Execution risk around cost discipline and operating expense reductions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247159 |
Track record
25 reports on ZYME
5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers